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PSA testing for men at average risk of prostate cancer
Abstract

Prostate-specific antigen (PSA) testing of men at normal risk of prostate cancer is one of the most contested
issues in cancer screening. There is no formal screening program, but testing is common - arguably a practice
that ran ahead of the evidence. Public and professional communication about PSA screening has been highly
varied and potentially confusing for practitioners and patients alike. There has been much research and policy
activity relating to PSA testing in recent years. Landmark randomised controlled trials have been reported;
authorities - including the 2013 Prostate Cancer World Congress, the Prostate Cancer Foundation of
Australia, Cancer Council Australia, and the National Health and Medical Research Council - have made or
endorsed public statements and/or issued clinical practice guidelines; and the US Preventive Services Task
Force is revising its recommendations. But disagreement continues. The contention is partly over what the
new evidence means. It is also a result of different valuing and prioritisation of outcomes that are hard to
compare: prostate cancer deaths prevented (a small and disputed number); prevention of metastatic disease
(somewhat more common); and side-effects of treatment such as incontinence, impotence and bowel trouble
(more common again). A sizeable proportion of men diagnosed through PSA testing (somewhere between
20% and 50%) would never have had prostate cancer symptoms sufficient to prompt investigation; many of
these men are older, with competing comorbidities. It is a complex picture. Below are four viewpoints from
expert participants in the evolving debate, commissioned for this cancer screening themed issue of Public
Health Research & Practice. We asked the authors to respond to the challenge of PSA testing of
asymptomatic, normal-risk men. They raise important considerations: uncertainty, harms, the trustworthiness
and interpretation of the evidence, cost (e.g. of using multiparametric magnetic resonance imaging to triage
patients with elevated PSA), a likely bias towards intervention (particularly for cancer), and the potential to
limit harm by treating more conservatively (although this may not occur consistently). They provide
important insights, and disagree on some issues, but generally concur that men should decide for themselves
whether to be tested. It seems reasonable to support men's autonomy to make their own decisions based on
their own values. However, the support men might require to decide is likely to be considerable, and this
needs to be taken seriously in policy making.
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Prostate-specific antigen (PSA) testing of men at normal risk of prostate
cancer is one of the most contested issues in cancer screening. There is no
formal screening program, but testing is common – arguably a practice that
ran ahead of the evidence. Public and professional communication about PSA
screening has been highly varied and potentially confusing for practitioners and
patients alike.

Key points
• There is no formal prostate cancer screening
program, but prostate-specific antigen (PSA)
testing is common in Australia and some other
jurisdictions and there are NHMRC approved
Australian guidelines for PSA testing
• During the past 5 years, new evidence and
new guidance have been produced regarding
PSA testing of men at average risk of
prostate cancer
• Considerable uncertainty and disagreement
remain about what the evidence shows, and
about whether asymptomatic men should
be tested
• A commonly proposed solution is to ensure
that men are well informed before they
decide whether to test, but the complexity,
uncertainty and very different outcomes being
weighed up suggest that this would require
considerable support

There has been much research and policy activity relating to PSA testing in recent
years. Landmark randomised controlled trials have been reported; authorities
– including the 2013 Prostate Cancer World Congress, the Prostate Cancer
Foundation of Australia, Cancer Council Australia, and the National Health and
Medical Research Council – have made or endorsed public statements and/or
issued clinical practice guidelines; and the US Preventive Services Task Force is
revising its recommendations. But disagreement continues.
The contention is partly over what the new evidence means. It is also a result of
different valuing and prioritisation of outcomes that are hard to compare: prostate
cancer deaths prevented (a small and disputed number); prevention of metastatic
disease (somewhat more common); and side-effects of treatment such as
incontinence, impotence and bowel trouble (more common again). A sizeable
proportion of men diagnosed through PSA testing (somewhere between 20%
and 50%) would never have had prostate cancer symptoms sufficient to prompt
investigation; many of these men are older, with competing comorbidities. It is a
complex picture.
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Below are four viewpoints from expert participants in the evolving debate,
commissioned for this cancer screening themed issue of Public Health Research
& Practice. We asked the authors to respond to the challenge of PSA testing of
asymptomatic, normal-risk men. They raise important considerations: uncertainty,
harms, the trustworthiness and interpretation of the evidence, cost (e.g. of using
multiparametric magnetic resonance imaging to triage patients with elevated
PSA), a likely bias towards intervention (particularly for cancer), and the potential
to limit harm by treating more conservatively (although this may not occur
consistently). They provide important insights, and disagree on some issues, but
generally concur that men should decide for themselves whether to be tested.
It seems reasonable to support men’s autonomy to make their own decisions
based on their own values. However, the support men might require to decide is
likely to be considerable, and this needs to be taken seriously in policy making.

View from a cancer epidemiologist
– by Bruce K Armstrong

the harms from PSA testing”.1 They were approved by
Australia’s National Health and Medical Research Council
on 2 November 2015.1 Early management was included
because early management decisions can influence the
realisation of assumed benefits and known harms of
PSA testing.
The PCFA and CCA expert advisory panel made two
important early decisions: that a national PSA testing
program akin to the national breast cancer screening
program (for example) would not be recommended, and
that the reported results of the European Randomized
Study of Screening for Prostate Cancer (ERSPC)
would provide the evidence base for its PSA testing
recommendations. The ERSPC is the largest study
addressing PSA test efficacy, and one of the two largest,
and the most recent, to report prostate cancer mortality
reduction in PSA-tested, average-risk men. This was a
necessary decision because only the ERSPC or statistical
models based on its results, rightly or wrongly, can inform
recommendations about the age range for, and frequency
of, PSA testing, and the PSA level above which further
investigation is recommended.
The guidelines make no recommendation about
whether men should be routinely offered PSA testing. Their
key testing recommendation is: “For men at average risk
of prostate cancer who have been informed of the benefits
and harms of testing and who decide to undergo regular
testing for prostate cancer, offer PSA testing every 2 years
from age 50 to age 69, and offer further investigation if total
PSA is greater than 3.0 ng/mL”. Very importantly, they also
recommend that the responsible clinical practitioner “offer
evidence-based decisional support to men considering
whether or not to have a PSA test, including the opportunity
to discuss the benefits and harms of PSA testing before
making the decision”. Guidance is given as to how the
PSA testing recommendation might be modified for
men at higher than average risk of prostate cancer, and
recommendations are made on management of men who
have a PSA >3.0 ng/mL or a biopsy diagnosis of prostate
cancer, aiming at all times to obtain a balance between the
benefits hoped for and the possible harms.
There is, as yet, no formal plan to evaluate
implementation of the guidelines in practice or whether the
assumed benefits of PSA testing are occurring, or whether
the benefits are even increasing and harms decreasing.

That early detection of disease is good is held as true
by most health professionals and most people. It is not
surprising, therefore, that early detection action runs
ahead of evidence of early detection benefit. This is true
of all national screening programs for cancers in Australia
– cervical cancer, breast cancer and colorectal cancer –
and it is true of prostate cancer, among others, for which
there is no formal national program. The urges of clinicians
to find cancer early and of people to avoid death from
the ‘big C’ are so great that it is also not surprising that
cancer screening without evidence of benefit persists,
despite evidence or a strong presumption of harm. The
principal harms are investigation and sometimes treatment
based on a false-positive test; clinical delay and perhaps
poorer outcomes after a false-negative test; and detection,
diagnosis and treatment of cancers that would otherwise
have never affected life or health (overdiagnosis).
How should public health policy tackle prostate-specific
antigen (PSA) testing for the early detection of prostate
cancer? How do we proceed when there is uncertain
benefit and certain harm, when up to 21% of Australian
men aged 45–74 participate in screening each year and
may benefit, and 19% aged over 74 also participate and
probably won’t? Ban it? Regulate it? Or do nothing? (Note:
these percentages were calculated from data on claims for
PSA tests [item number 66655] processed by Medicare
Australia in 2015–16 [medicarestatistics.humanservices.
gov.au/statistics] and Australian Bureau of Statistics
tables of estimated resident population by age and sex
at 30 June 2015 and 30 June 2016 [ABS report series
3101.0 Australian Demographic Statistics], with the value
7.5 added to each calculated percentage to correct for the
effect of Medicare’s ‘episode coning’ policy on recording of
pathology items claimed for.)
Faced with these choices and the lack of other
likely action, Cancer Council Australia (CCA) and the
Prostate Cancer Foundation of Australia (PCFA) chose
to ‘regulate’ by developing clinical practice guidelines
for PSA testing and early management of test-detected
prostate cancer. These nonbinding guidelines aimed “to
maximise the benefits, if there are benefits, and minimise
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make screening cost-effective6, will prove acceptable to
most clinicians and patients remains to be seen. The most
important reason for not rejecting PSA screening is that
there is variation in how men see the trade-offs between
possible benefits and harms. When men were fully informed
about the trade-offs in a decision making process including
a patient decision aid, and could answer key knowledge
questions accurately, about a third still wanted a PSA test.8
Key points to cover in a conversation between a man and a
clinician have been previously reviewed.5
Some health systems will reasonably decide not to
make PSA screening generally available because their
limited resources can be used more effectively in other
ways. However, if PSA screening is available, letting
informed men help decide whether a PSA test is right for
them seems the most patient-centred way forward. After
all, they are the ones who must live with the consequences
of the decision.

We might reasonably hope to see a fall in Australia’s very
high prostate cancer incidence rates following guideline
implementation because of a fall in prostate cancer
overdiagnosis due to the recommended narrower age
range for, and lower frequency of, PSA testing than has
been common in recent Australian practice. Because of the
lack of any recommendation for or against PSA testing, and
PSA’s uncertain screening efficacy, any prediction of the
prostate cancer mortality trend would be pure guesswork.

View from the United States – by
Michael J Barry
There is a lot not to like about screening for prostate
cancer with the PSA test. In the ERSPC, arguably the
highest-quality trial, although not without its faults2, benefits
were modest. After 13 years, 1.28 fewer prostate cancer
deaths per 1000 men were observed with screening, with
no decrease in overall mortality.3 Heterogeneity among
ERSPC countries in screening protocols, treatments and
outcomes has raised questions about the magnitude
of benefit actually attributable to PSA testing.4 On the
other hand, the harms of screening are relatively high,
with 31 additional cases of prostate cancer needing to
be detected per prostate cancer death prevented.3 Men
are not used to thinking of PSA screening as ‘causing’
cancer, but, for practical purposes, the substantially
higher incidence with screening means just that. The
higher incidence reflects more prostate biopsies, with
short-term complications of haematuria, haematochezia,
haematospermia and infections. The main harms, however,
come from the treatment of men found to have prostate
cancer, including substantial risks of erectile dysfunction
and incontinence. Most of these cancers are never
destined to cause morbidity or mortality5, and the men
who harbour them can only be harmed by early detection.
Finally, at least in relation to practices in the US, PSA
screening is not cost-effective.6
That all sounds like a pretty good argument for not
screening, right? Perhaps. However, the absolute benefit
from prostate cancer screening, if the ERSPC estimate
is correct, is not dissimilar to the benefit of screening for
breast cancer, and reducing overall mortality may be too
high a bar for any screening test. Modelling strategies, and
the reduction in metastases seen in the ERSPC, suggest
that the absolute benefit may be greater over a longer
time. Strategies being considered for maintaining most
of the benefits while reducing the harms include testing
less frequently (the screening interval in the ERSPC was
2–4 years), higher biopsy thresholds and, most importantly,
active surveillance for men with low-risk cancers. These
strategies to mitigate harm are not perfect and will come
at the price of slightly higher risks of bad outcomes. For
example, in the ProtecT study, active monitoring had the
same cancer-specific mortality as surgery or radiation
over 10 years (about 1%) but a higher risk of metastases
(6% versus 3%).7 Whether these strategies, which may

View from urologists – by Mark
Frydenberg and Robert A Gardiner
Before considering selective screening for prostate cancer,
the question to be asked is whether a diagnosis will
benefit the patient. The answer can only be determined
by establishing whether the patient accepts the risks and
potential side-effects of the diagnostic and treatment
processes, appreciates the likelihood of cancer (if
present) to affect his health and wellbeing, and can make
a value judgement about what is really important to him.
Consequently, there is no place for mass population or socalled opportunistic PSA screening.
The large majority of men investigated for prostate
cancer are asymptomatic and do not have suspected
malignancy based on a digital rectal examination. Because
of the long natural history of most tumours, a 7–10-year life
expectancy following treatment (and therefore diagnosis)
is considered warranted before considering PSA testing.
Pertinently, many patients have significant or latent
comorbidities that will significantly affect their survival within
a decade, so they will not live long enough to achieve a
survival benefit.9 -12
Serious health problems are not uncommon in middleaged and elderly males, along with lifestyle-related factors
such as smoking and obesity, which have yet to overtly
affect morbidity and mortality. A poor appreciation of
individual life expectancy is not just limited to patients,
as many clinicians are also overoptimistic and give
patients ‘the benefit of the doubt’ when recommending
investigations and treatments.12 To introduce some
objectivity to overall patient prognosis, life expectancy
tables13,14 may be helpful, although they are population
based and do not take into account an individual’s
comorbidities or sociodemographic factors.
Selective screening involves identifying men who are at
risk of developing clinically significant prostate cancer, and
are likely to benefit from a prostate cancer diagnosis and
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monitoring confirms the results of the Prostate Cancer
Intervention Versus Observation Trial (PIVOT), the only other
randomised trial done in the era of PSA screening tests.29
It found no significant prostate cancer–specific mortality
or overall survival benefit for radical surgery over active
monitoring at 12 years, confirmed at 19.5 years follow-up.30
PIVOT showed an absolute risk reduction of 5.5% (95%
confidence interval [CI] –1.5, 12.4%; p = 0.06) for all-cause
mortality (61.3% in patients treated with prostatectomy
vs 66.8% in patients who had active monitoring) and
an absolute risk reduction of 4% (95% CI –0.2%, 8.3%;
p = 0.06) for prostate cancer–specific mortality (7.4% in
patients treated with prostatectomy vs 11.4% in patients
who had active monitoring). Although surgery reduced
the need for treatment of progressive disease, there were
increased treatment-related long-term complications such
as urinary incontinence and erectile dysfunction. The
dissemination of these results to every man over 40 will aid
their informed decision making about PSA testing, and may
reduce the overdiagnosis, overtreatment, and significant
and immediate physical and psychological harms caused to
many of them.31
One of the reasons for this widespread testing has been
that one of the two large randomised studies of screening
for prostate cancer with PSA, the ERSPC3, showed a
small survival benefit for screening. However, it has been
suggested by the chief medical and scientific officer of
the American Cancer Society that this study has flaws
and unintended biases, such as a large disparity between
primary treatment with androgen deprivation monotherapy
given to similar-risk patients in each arm.32 The call for an
independent review of the mortality data was repeated in
a recent review.33 Conversely, the other major randomised
screening study34, which showed no benefit for screening,
was recently found to have major contamination of the
control arm, in which 90% of men had a PSA test during
the study period.35 This makes its results less reliable,
although it is important to note that there were still 22%
more cancers diagnosed in the screening arm after 2 years,
with no associated survival benefit.
Despite the efforts of many urologists to reduce
overdiagnosis and overtreatment, some urology groups
suggest that all men over 40 should consider a screening
PSA test36, even when we know that 24.4% of men with
a ‘normal’ PSA are diagnosed with prostate cancer when
they have a biopsy37 and it is a common finding in this age
group at autopsy.38 Many are advised to consider radical
treatment, with all the possible adverse consequences,
for a disease that kills 1 in 7 (2–3% of all men) at a median
age of 82.414 and for which there is still no proven survival
benefit for radical intervention.
This is poor public health policy. The USPSTF should
not reverse its previous advice.39

therefore PSA testing. As we have previously reported15,
a family history (particularly in first-degree relatives) is
well recognised to predispose to a future diagnosis of
prostate cancer, but a PSA >1.5 ng/mL for men aged
less than 50 years is regarded as even more predictive
than either family history or ethnicity.16 Hereditary prostate
cancers occur more commonly than any other tumour
diagnosed – on average, detected 6 years earlier than for
sporadic cancer.17 Patients with a family history of germ-line
mutations in the family-susceptibility genes BRCA1 and
BRCA2 have a significantly increased risk of developing
this malignancy, tend to present at a younger age, and
tend to have more aggressive disease and poorer survival
outcomes.18–22
Increasingly, multiparametric magnetic resonance
imaging (mpMRI) is being used to triage patients with an
elevated PSA. A combination of anatomical (T2-weighted)
images with at least two of the three functional MRI
parameters (diffusion-weighted imaging, dynamic contrastenhanced imaging and spectroscopy) has been estimated
to identify approximately 90% of moderate- to high-risk
lesions, but is less reliable for detecting small (<0.5 cubic
centimetres) and lower risk tumours.23-25 Limitations to using
mpMRI are the level of accuracy of MRI interpretation and
cost. However, until a cheaper and comparably accurate
diagnostic test replaces PSA testing, the combination of
PSA testing and mpMRI will remain the initial investigation
of choice before biopsy.
It is easy to overlook or underestimate the quality-oflife impacts, which range from the anguish of possibly
harbouring a malignancy to the uncommon but potentially
devastating effects of infection associated with a biopsy,
to the side-effects of the various treatments. Some men
may rather risk a cancer spreading (especially in a cancer
of lower histological grade) and remain untreated than risk
losing their sexual or urinary abilities, in addition to other
changes in bodily function that can affect social confidence
and self-esteem. Consequently, it is imperative at the outset
to evaluate and respect decisions made with respect to
quality of life26 when deciding whether to test for prostate
cancer.

View from an oncologist – by Ian
Haines
In 2012, the US Preventive Services Task Force (USPSTF)
downgraded its recommendation for screening using
PSA testing from C to D.27 Since that advice, the muchanticipated ProtecT study28 has been published. It
randomised 1643 men equally between radical surgery,
radical radiation and active monitoring, and reported results
at 10 years. It revealed that only 1% of men with early-stage
prostate cancer died of their disease in the first 10 years
after diagnosis, irrespective of treatment and the usual
prognostic factors.
Although treatment achieved a significant reduction in
local disease progression and metastases, the lack of a
significant survival benefit for radical surgery over active
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